Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06956404 · ClinicalTrials.gov registry record · NA

tPBM in Older Adults With Traumatic Brain Injury

A NA study of Traumatic Brain Injury, sponsored by NYU Langone Health.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT06956404 is a NA study of Traumatic Brain Injury that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 70 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06956404, a NA study of Traumatic Brain Injury, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate the effect of transcranial photobiomodulation (tPBM) in older patients with chronic traumatic brain injury (TBI). The study aims to examine the effect of tPBM on prefrontal cerebral blood flow (CBF) and executive function (EF)

Conditions Studied

Interventions

  • DEVICE Transcranial photobiomodulator (tPBM)
  • DEVICE Transcranial photobiomodulator (tPBM) in sham mode

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2025-12-29
Est. Completion 2028-07
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT06956404

The ClinicalTrials.gov registry entry for NCT06956404 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (75% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which Transcranial photobiomodulator (tPBM) is the first listed.

NCT06956404 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06956404 about?

NCT06956404 is a clinical study titled "tPBM in Older Adults With Traumatic Brain Injury". The purpose of this study is to evaluate the effect of transcranial photobiomodulation (tPBM) in older patients with chronic traumatic brain injury (TBI). The study aims to examine the effect of tPBM on prefrontal cerebral blood flow (CBF) and executive function (EF)

What is the current status of trial NCT06956404?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2025-12-29. Estimated completion is 2028-07.

What conditions does trial NCT06956404 study?

This clinical trial studies the following conditions: Traumatic Brain Injury.

What interventions are being tested in trial NCT06956404?

The interventions under investigation include: Transcranial photobiomodulator (tPBM) (DEVICE), Transcranial photobiomodulator (tPBM) in sham mode (DEVICE).

Who is sponsoring clinical trial NCT06956404?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06956404 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Traumatic Brain Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.